Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes

L. Tentori, G. Graziani, Steven A. Porcelli, M. Sugita, M. B. Brenner, R. Madaio, E. Bonmassar, A. Giuliani, A. Aquino

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

In recent years, it has been shown that a nonclassical, major histocompatibility complex-independent system (i.e., CD1-restricted T-cell responses) is involved in T-cell immunity against nonpeptide antigens. The CD1 system appears to function by presenting microbial lipid antigens to specific T cells, and the antigens so far identified include several known constituents of mycobacterial cell walls. Among the four known human CD1 isoforms, the CD1b protein is the best characterized with regard to its antigen-presenting function. Expression of CD1b is upregulated on human blood monocytes upon exposure to granulocyte/macrophage-colony stimulating factor, alone or in combination with interleukin-4 (IL-4) (S. A. Porcelli, Adv. Immunol. 59:1-98, 1995). Rifampin (RFP) and its derivatives are widely used for chemoprophylaxis or chemotherapy against Mycobacterium tuberculosis. However, this agent was found to reduce the mitogen responsiveness of human B and T lymphocytes, chemotaxis, and delayed-type hypersensitivity. The present study extends the immunopharmacological profile of RFP by examining its effects on CD1b expression by human peripheral blood monocytes exposed to GM- CSF plus IL-4. The results showed that clinically attainable concentrations (i.e., 2 or 10 μg/ml for 24 h) of the agent produced a marked increase in CD1b expression on the plasma membrane, as evaluated by fluorescence- activated cell sorter analysis, whereas it had no effect on cytosolic fractions, as indicated by Western blot analysis. This was found to be the result of increased CD1b gene expression, as shown by Northern blot analysis of CD1b mRNA. These results suggest that RFP could be of potential value in augmenting the CD1b-restricted antigen recognition system, thereby enhancing protective cellular immunity to M. tuberculosis.

Original languageEnglish (US)
Pages (from-to)550-554
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume42
Issue number3
StatePublished - Mar 1998
Externally publishedYes

Fingerprint

Rifampin
Monocytes
Cytokines
T-Lymphocytes
Granulocyte-Macrophage Colony-Stimulating Factor
Mycobacterium tuberculosis
Antigens
Interleukin-4
Viral Tumor Antigens
Chemoprevention
Delayed Hypersensitivity
Chemotaxis
Major Histocompatibility Complex
Mitogens
Cellular Immunity
Northern Blotting
Cell Wall
Immunity
Protein Isoforms
B-Lymphocytes

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Tentori, L., Graziani, G., Porcelli, S. A., Sugita, M., Brenner, M. B., Madaio, R., ... Aquino, A. (1998). Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes. Antimicrobial Agents and Chemotherapy, 42(3), 550-554.

Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes. / Tentori, L.; Graziani, G.; Porcelli, Steven A.; Sugita, M.; Brenner, M. B.; Madaio, R.; Bonmassar, E.; Giuliani, A.; Aquino, A.

In: Antimicrobial Agents and Chemotherapy, Vol. 42, No. 3, 03.1998, p. 550-554.

Research output: Contribution to journalArticle

Tentori, L, Graziani, G, Porcelli, SA, Sugita, M, Brenner, MB, Madaio, R, Bonmassar, E, Giuliani, A & Aquino, A 1998, 'Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes', Antimicrobial Agents and Chemotherapy, vol. 42, no. 3, pp. 550-554.
Tentori, L. ; Graziani, G. ; Porcelli, Steven A. ; Sugita, M. ; Brenner, M. B. ; Madaio, R. ; Bonmassar, E. ; Giuliani, A. ; Aquino, A. / Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes. In: Antimicrobial Agents and Chemotherapy. 1998 ; Vol. 42, No. 3. pp. 550-554.
@article{6d126ff74c7241be8acf73df3cd404d1,
title = "Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes",
abstract = "In recent years, it has been shown that a nonclassical, major histocompatibility complex-independent system (i.e., CD1-restricted T-cell responses) is involved in T-cell immunity against nonpeptide antigens. The CD1 system appears to function by presenting microbial lipid antigens to specific T cells, and the antigens so far identified include several known constituents of mycobacterial cell walls. Among the four known human CD1 isoforms, the CD1b protein is the best characterized with regard to its antigen-presenting function. Expression of CD1b is upregulated on human blood monocytes upon exposure to granulocyte/macrophage-colony stimulating factor, alone or in combination with interleukin-4 (IL-4) (S. A. Porcelli, Adv. Immunol. 59:1-98, 1995). Rifampin (RFP) and its derivatives are widely used for chemoprophylaxis or chemotherapy against Mycobacterium tuberculosis. However, this agent was found to reduce the mitogen responsiveness of human B and T lymphocytes, chemotaxis, and delayed-type hypersensitivity. The present study extends the immunopharmacological profile of RFP by examining its effects on CD1b expression by human peripheral blood monocytes exposed to GM- CSF plus IL-4. The results showed that clinically attainable concentrations (i.e., 2 or 10 μg/ml for 24 h) of the agent produced a marked increase in CD1b expression on the plasma membrane, as evaluated by fluorescence- activated cell sorter analysis, whereas it had no effect on cytosolic fractions, as indicated by Western blot analysis. This was found to be the result of increased CD1b gene expression, as shown by Northern blot analysis of CD1b mRNA. These results suggest that RFP could be of potential value in augmenting the CD1b-restricted antigen recognition system, thereby enhancing protective cellular immunity to M. tuberculosis.",
author = "L. Tentori and G. Graziani and Porcelli, {Steven A.} and M. Sugita and Brenner, {M. B.} and R. Madaio and E. Bonmassar and A. Giuliani and A. Aquino",
year = "1998",
month = "3",
language = "English (US)",
volume = "42",
pages = "550--554",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes

AU - Tentori, L.

AU - Graziani, G.

AU - Porcelli, Steven A.

AU - Sugita, M.

AU - Brenner, M. B.

AU - Madaio, R.

AU - Bonmassar, E.

AU - Giuliani, A.

AU - Aquino, A.

PY - 1998/3

Y1 - 1998/3

N2 - In recent years, it has been shown that a nonclassical, major histocompatibility complex-independent system (i.e., CD1-restricted T-cell responses) is involved in T-cell immunity against nonpeptide antigens. The CD1 system appears to function by presenting microbial lipid antigens to specific T cells, and the antigens so far identified include several known constituents of mycobacterial cell walls. Among the four known human CD1 isoforms, the CD1b protein is the best characterized with regard to its antigen-presenting function. Expression of CD1b is upregulated on human blood monocytes upon exposure to granulocyte/macrophage-colony stimulating factor, alone or in combination with interleukin-4 (IL-4) (S. A. Porcelli, Adv. Immunol. 59:1-98, 1995). Rifampin (RFP) and its derivatives are widely used for chemoprophylaxis or chemotherapy against Mycobacterium tuberculosis. However, this agent was found to reduce the mitogen responsiveness of human B and T lymphocytes, chemotaxis, and delayed-type hypersensitivity. The present study extends the immunopharmacological profile of RFP by examining its effects on CD1b expression by human peripheral blood monocytes exposed to GM- CSF plus IL-4. The results showed that clinically attainable concentrations (i.e., 2 or 10 μg/ml for 24 h) of the agent produced a marked increase in CD1b expression on the plasma membrane, as evaluated by fluorescence- activated cell sorter analysis, whereas it had no effect on cytosolic fractions, as indicated by Western blot analysis. This was found to be the result of increased CD1b gene expression, as shown by Northern blot analysis of CD1b mRNA. These results suggest that RFP could be of potential value in augmenting the CD1b-restricted antigen recognition system, thereby enhancing protective cellular immunity to M. tuberculosis.

AB - In recent years, it has been shown that a nonclassical, major histocompatibility complex-independent system (i.e., CD1-restricted T-cell responses) is involved in T-cell immunity against nonpeptide antigens. The CD1 system appears to function by presenting microbial lipid antigens to specific T cells, and the antigens so far identified include several known constituents of mycobacterial cell walls. Among the four known human CD1 isoforms, the CD1b protein is the best characterized with regard to its antigen-presenting function. Expression of CD1b is upregulated on human blood monocytes upon exposure to granulocyte/macrophage-colony stimulating factor, alone or in combination with interleukin-4 (IL-4) (S. A. Porcelli, Adv. Immunol. 59:1-98, 1995). Rifampin (RFP) and its derivatives are widely used for chemoprophylaxis or chemotherapy against Mycobacterium tuberculosis. However, this agent was found to reduce the mitogen responsiveness of human B and T lymphocytes, chemotaxis, and delayed-type hypersensitivity. The present study extends the immunopharmacological profile of RFP by examining its effects on CD1b expression by human peripheral blood monocytes exposed to GM- CSF plus IL-4. The results showed that clinically attainable concentrations (i.e., 2 or 10 μg/ml for 24 h) of the agent produced a marked increase in CD1b expression on the plasma membrane, as evaluated by fluorescence- activated cell sorter analysis, whereas it had no effect on cytosolic fractions, as indicated by Western blot analysis. This was found to be the result of increased CD1b gene expression, as shown by Northern blot analysis of CD1b mRNA. These results suggest that RFP could be of potential value in augmenting the CD1b-restricted antigen recognition system, thereby enhancing protective cellular immunity to M. tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=0031894346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031894346&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 550

EP - 554

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -